These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 29025978)

  • 21. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma.
    Wang C; Li Y; Chen H; Zhang J; Zhang J; Qin T; Duan C; Chen X; Liu Y; Zhou X; Yang J
    Cancer Lett; 2017 Aug; 402():131-141. PubMed ID: 28602979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo.
    Szabo E; Schneider H; Seystahl K; Rushing EJ; Herting F; Weidner KM; Weller M
    Neuro Oncol; 2016 Sep; 18(9):1242-52. PubMed ID: 27009237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
    Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
    Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
    Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
    Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.
    Li XQ; Ouyang ZG; Zhang SH; Liu H; Shang Y; Li Y; Zhen YS
    Cancer Biol Ther; 2014 Apr; 15(4):398-408. PubMed ID: 24424202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells.
    Aoki S; Cho SH; Ono M; Kuwano T; Nakao S; Kuwano M; Nakagawa S; Gao JQ; Mayumi T; Shibuya M; Kobayashi M
    Anticancer Drugs; 2006 Mar; 17(3):269-78. PubMed ID: 16520655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
    Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
    Fan Y; Peng A; He S; Shao X; Nie C; Chen L
    J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The biflavonoid amentoflavone inhibits neovascularization preventing the activity of proangiogenic vascular endothelial growth factors.
    Tarallo V; Lepore L; Marcellini M; Dal Piaz F; Tudisco L; Ponticelli S; Lund FW; Roepstorff P; Orlandi A; Pisano C; De Tommasi N; De Falco S
    J Biol Chem; 2011 Jun; 286(22):19641-51. PubMed ID: 21471210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice.
    Malik AK; Baldwin ME; Peale F; Fuh G; Liang WC; Lowman H; Meng G; Ferrara N; Gerber HP
    Blood; 2006 Jan; 107(2):550-7. PubMed ID: 16189273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined Anti-PLGF and Anti-Endostatin Treatments Inhibit Ocular Hemangiomas.
    Jiang H; Wu X; Wang H; Huang C; Zhang L
    Cell Physiol Biochem; 2015; 36(3):930-6. PubMed ID: 26088746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
    Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth.
    Ceci C; Tentori L; Atzori MG; Lacal PM; Bonanno E; Scimeca M; Cicconi R; Mattei M; de Martino MG; Vespasiani G; Miano R; Graziani G
    Nutrients; 2016 Nov; 8(11):. PubMed ID: 27879653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
    Camp ER; Yang A; Liu W; Fan F; Somcio R; Hicklin DJ; Ellis LM
    Clin Cancer Res; 2006 Apr; 12(8):2628-33. PubMed ID: 16638876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK; Piao Y; de Groot JF
    Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.
    Brave SR; Eberlein C; Shibuya M; Wedge SR; Barry ST
    Angiogenesis; 2010 Dec; 13(4):337-47. PubMed ID: 20953695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.